A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors

  title={A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors},
  author={K. Mody and A. Mansfield and L. Vemireddy and P. Nygren and Joachim Gulbo and M. Borad},
  journal={Investigational New Drugs},
SummaryIntroduction VLX600 is a novel iron chelator designed to interfere with intracellular iron metabolism, leading to inhibition of mitochondrial respiration and bioenergetic catastrophe and resultant tumor cell death. Methods We conducted a multicenter, phase 1, dose escalation study to determine the safety and adverse event profile and the maximum tolerated dose and recommended phase 2 dose of VLX600. Other endpoints included pharmacokinetics, and preliminary evidence of anti-cancer… Expand
Iron chelators in cancer therapy
This review examines and discusses the various iron chelators that have been trialled for cancer therapy including both preclinical and clinical studies, and the successes and shortcomings of each of the chelator and their use in combination therapies are highlighted. Expand
Re-polarization of immunosuppressive macrophages to tumor-cytotoxic macrophages by repurposed metabolic drugs
By targeting cell metabolism, macrophages could be re-polarized from M2- into an anti-tumoral M1-like phenotype and that M0-to-M2 polarization could be prevented. Expand
Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology
Whether iron modulation represents a useful approach for treating metastatic disease and whether it could be employed in combination with existing targeted drugs and immune-based therapies to enhance their efficacy is addressed. Expand
Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases
Deferiprone, deferoxamine, deferasirox and other chelating drugs can offer therapeutic solutions for most diseases associated with iron metabolism including iron overload and deficiency, neurodegeneration and cancer, the detoxification of xenobiotic metals and most diseasesassociated with free radical pathology. Expand
From old to new - Repurposing drugs to target mitochondrial energy metabolism in cancer.
This review article summarizes current concepts and therapeutic opportunities in the area of targeting aerobic mitochondrial energy metabolism in cancer by considering only those drugs which predominantly inhibit oxidative phosphorylation. Expand
VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases
It is shown that VLX600, a small molecule that has been in a phase I clinical trial, disrupts HR and synergizes with PARPis and platinum compounds in ovarian cancer cells, and that pharmacologically targeting KDM family members with VLx600 may be a potential novel strategy to therapeutically induce HR defects in ovarian cancers. Expand
Reductive Stress, Bioactive Compounds, Redox-Active Metals and Dormant Tumor Cell Biology to Develop Redox-Based Tools for the Treatment of Cancer.
The latest experimental evidence regarding redox biology in cancer treatment is reviewed and its potential impact in the development of improved and more effective antineoplastic therapies is analyzed. Expand
Why All the Fuss about Oxidative Phosphorylation (OXPHOS)?
This Perspective provides an overview of the structure and function of OXPHOS complexes, their biological functions in cancer, relevant research tools and models, as well as the limitations of OxPHOS as drug targets. Expand
BRCA1 Deficiency Upregulates NNMT Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents.
It is shown that reducing BRCA1 expression led to metabolic reprogramming of ovarian cancer cells, causing decreased mitochondrial respiration and reduced ATP levels, and suggest that inhibition of energy metabolism may be a potential strategy to selectively target BRCa1-deficient high-grade serous ovarian cancer (HGSOC), which is characterized by frequent B RCA1 loss and NNMT overexpression. Expand


Phase II study of Triapine® in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161)
The study closed, at the end of stage 1, as it did not meet the minimal efficacy criteria to proceed and further evaluation of Triapine at this dose and schedule in patients with advanced kidney cancer is not recommended. Expand
A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics
Results indicate that the novel Fe chelators have potent and broad antitumor activity and can overcome resistance to established chemotherapeutics because of their unique mechanism of action. Expand
Iron chelators as therapeutic agents for the treatment of cancer.
The high anti-tumor activity observed with these ligands certainly suggests further development of chelators as anti-cancer agents is warranted. Expand
Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.
The findings demonstrate the superiority of Triapine over hydroxyurea as an anticancer agent and suggest that prevention byTriapine of repair of DNA lesions created by agents that damage DNA may result in efficacious drug combinations for the treatment of cancer. Expand
Ribonucleotide Reductase Expression in Cervical Cancer: A Radiation Therapy Oncology Group Translational Science Analysis
It is suggested that RNR subunit expression may discriminate cervical cancer phenotype and radiochemotherapy outcome and future RNR biomarker studies are warranted. Expand
Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes.
Copper binding was essential for the potent antitumor activity of Dp44mT, as coincubation with nontoxic copper chelators markedly attenuated its cytotoxicity. Expand
Resistance to Chemotherapy in Cancer: A Complex and Integrated Cellular Response
This review explores the phenomenon of drug resistance in cancer and highlights the gap between in vitro and in vivo observations, presenting a major obstacle in overcoming drug resistance and restoring sensitivity to chemotherapy. Expand
Novel chelators for cancer treatment: where are we now?
The absorption of iron from the gut; its transport, metabolism, and homeostasis in mammals; and the molecular pathways involved are examined. Expand
The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture.
The recent development of new drugs that are nontoxic until they are activated in the hypoxic cell opens a new era of selective cancer therapy. Expand
The role of iron in cell cycle progression and the proliferation of neoplastic cells.
This review will focus on the molecular mechanisms induced following Fe chelation and the role of Fe in cell cycle progression. Expand